The Commission may enter into agreements concerning the administration of this Part with The Pharmacy Guild of Australia and, subject to this Part, shall abide by such agreements.
47 Transitional provision relating to the Veterans’ Affairs Pharmaceutical Benefits Schemes (Electronic Prescriptions and Active Ingredient Prescribing) Amendment Instrument 2019
(1) This section applies in relation to a prescription for the supply of a Pharmaceutical benefit that is written before 1 February 2021.
(2) Despite the amendments of section 11A of the Repatriation Pharmaceutical Benefits Scheme made by Part 2 of Schedule 1 to the Veterans’ Affairs Pharmaceutical Benefits Schemes (Electronic Prescriptions and Active Ingredient Prescribing) Amendment Instrument 2019, a prescription that is not a medication chart prescription is taken to have been written in accordance with section 11A if the prescription is written in accordance with that section as in force immediately before 31 October 2019.
(3) Despite the amendments of section 11B of the Repatriation Pharmaceutical Benefits Scheme made by Part 2 of Schedule 1 to the Veterans’ Affairs Pharmaceutical Benefits Schemes (Electronic Prescriptions and Active Ingredient Prescribing) Amendment Instrument 2019, a prescription that is a medication chart prescription is taken to have been written in accordance with section 11B if the prescription is written in accordance with that section as in force immediately before 31 October 2019.
SCHEDULE 1 — INCORPORATED DOCUMENTS
The following documents are incorporated by reference into the Scheme in the form in which they exist from time to time:
3 2194L Alendronic acid with colecalciferol Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol
4 2224C Alendronic acid with colecalciferol Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol
5 2439J Dressing-foam with silver and silicone Dressings 10 cm x 10 cm, 5
6 2445Q Dressing-gelling fibre Dressings, non-woven, gelling fibre 15 cm x 15 cm, 5
7 2462N Dressing-gelling fibre Dressings, non-woven, gelling fibre 2 cm x 45 cm rope, 5
8 2470B Dressing-foam with silver and silicone Dressings, border, 10 cm x 10 cm, 5
9 2471C Dressing-hydrogel Dressing 10 cm x 10 cm
10 2486W Dressing-gelling fibre Dressings, non-woven, gelling fibre 10 cm x 10 cm, 10
11 2512F Dressing-antimicrobial-ribbon Dressing 1 cm x 50 cm
12 2525X Wound irrigation solution Solution containing betaine 0.1% with polihexanide 0.1%, 40 mL ampoule, 6
13 2529D Dressing-antimicrobial-ribbon Dressing 5 cm x 200 cm
14 2533H Dressing-antimicrobial-foam Dressing 10 cm x 10 cm
15 2797F Dressing-hydrofibre (alternate to alginates) Dressings 10 cm x 10 cm, 10
16 2803M Dressing-hydrofibre (alternate to alginates) Dressings 15 cm x 15 cm, 5
17 4004R Clotrimazole Cream 10 mg per g, 20 g
18 4010C Amorolfine hydrochloride Nail treatment kit containing nail lacquer 50 mg (base) per mL (5%), 5 mL, 60 isopropyl alcohol cleaning pads, 10 spatulas and 30 nail files
40 4131K Betamethasone Cream 1 mg (as valerate) per g, 30 g
41 4132L Betamethasone Ointment 1 mg (as valerate) per g, 30 g
42 4134N Imiquimod Cream 50 mg per g, 250 mg single use sachets, 12
43 4142B Calcium Tablet 600 mg (as carbonate)
44 4150K Bromazepam Tablet 3 mg
45 4151L Bromazepam Tablet 6 mg
46 4161B Chlorhexidine gluconate Mouth wash 2 mg per mL (0.2%), 250 mL
47 4175R Cetirizine hydrochloride Tablet 10 mg
48 4176T Carbamide peroxide Ear drops 65 mg per mL (6.5%), 12 mL
49 4180B Dichlorobenzene with chlorobutanol and arachis oil Ear drops, ortho-dichlorobenzene 140 mg per mL, para-dichlorobenzene 20 mg per mL, chlorobutanol hemihydrate 50 mg per mL, arachis oil 573 mg per mL, 10 mL
50 4196W Dressing-foam with silicone-heavy exudate Dressings 10 cm x 10 cm, 10
51 4199B Docusate sodium Ear drops 5 mg per mL (0.5%), 10 mL
52 4200C Docusate sodium Tablet 50 mg
53 4204G Chlorhexidine gluconate Mouth wash 2 mg per mL (0.2%), 300 mL
54 4207K Dressing-foam with silicone-heavy exudate Dressings 7.5 cm x 7.5 cm, 10
55 4216X Flunitrazepam Tablet 1 mg
56 4222F Fluorouracil Cream 50 mg per g (5%), 20 g
57 4230P Dressing-foam with silicone-heavy exudate Dressings 10 cm x 10 cm, 10
58 4233T Finasteride Tablet 5 mg
59 4237B Fexofenadine hydrochloride Tablet 60 mg
60 4238C Fexofenadine hydrochloride Tablet 120 mg
61 4239D Tapes-plaster adhesive (with silicone) Roll 2 cm x 3 m
62 4240E Tapes-plaster adhesive (with silicone) Roll 4 cm x 1.5 m
63 4243H Dressing-non-adherent Dressings, non-woven, with silicone 5 cm x 7.5 cm, 10
64 4244J Dressing-non-adherent Dressings, non-woven, with silicone 7.5 cm x 10 cm, 10
65 4246L Glycerol Suppositories 2.8 g, 12
66 4252T Dressing-foam-silver Dressings, adhesive, 7.5 cm x 7.5 cm, 10
67 4255Y Dressing-foam-silver Dressings, adhesive, 10 cm x 10 cm, 10
68 4258D Dressing-foam-silver Dressings, adhesive, 12.5 cm x 12.5 cm, 10
69 4259E Dressing-foam-silver Dressings, non-adhesive, 10 cm x 10 cm, 10
70 4263J Dressing-foam-silver Dressings 7.5 cm x 7.5 cm, 10
71 4266M Dressing-foam-silver Dressings 10 cm x 10 cm, 10
72 4270R Dressing-foam-silver Dressings 12.5 cm x 12.5 cm, 10
73 4275B Codeine with paracetamol Tablet containing codeine phosphate hemihydrate 8 mg with paracetamol 500 mg
74 4277D Alfuzosin hydrochloride Tablet 10 mg
75 4279F Hyoscine Injection containing hyoscine butylbromide 20 mg in 1 mL
76 4280G Ichthammol with zinc oxide Ointment 10 mg-150 mg per g (1%-15%), 50 g
77 4281H Ichthammol Cream 10 mg per g (1%), 50 g
78 4284L Infliximab Powder for I.V. infusion 100 mg
79 4285M Ispaghula husk Sachets 3.5 g, 30
80 4286N Codeine with aspirin Tablet containing codeine phosphate hemihydrate 8 mg with aspirin 300 mg
81 4303L Finasteride Tablet 5 mg
82 4306P Lubricating gel Tube 100 g
83 4307Q Sunscreens Cream 75 g
84 4308R Lidocaine Solution containing lidocaine hydrochloride 20 mg per mL (2%), 200 mL
296 10599W Paracetamol Oral liquid 240 mg per 5 mL, 200 mL
297 10831C Hydrocortisone Ointment containing hydrocortisone acetate 10 mg per g, 30 g
298 10832D Dressing-hydrofibre (alternate to alginates) Dressing 12.5 cm x 12.5 cm
299 10837J Dressing-hydrofibre (alternate to alginates) Dressing 10 cm x 10 cm
300 10847X Povidone-Iodine Dressing 9.5 cm x 9.5 cm
301 10849B Dressing alginate with manuka honey Dressing 10 cm x 10 cm
302 10854G Nystatin Oral suspension 100,000 units per mL, 24 mL
303 10857K Dressing alginate with manuka honey Ribbon 2.5 cm x 20 cm
304 11134B Sodium chloride with hypochlorous acid and sodium hypochlorite Solution containing sodium chloride 0.022% with hypochlorous acid 0.004% and sodium hypochlorite 0.004%, 250 mL
The endnotes provide information about this compilation and the compiled law.
The following endnotes are included in every compilation:
Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.
Editorial changes
The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.
If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.
Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the Legislation Act 2003.
If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.
ad = added or inserted
orig = original
am = amended
p = page(s)
amdt = amendment
para = paragraph(s)/subparagraph(s)
C[x] = Compilation No. x
/sub‑subparagraph(s)
ch = Chapter(s)
pres = present
cl = clause(s)
prev = previous
cont. = continued
(prev…) = previously
def = definition(s)
pt = Part(s)
Dict = Dictionary
r = regulation(s)/Court rule(s)
disallowed = disallowed by Parliament
reloc = relocated
div = Division(s)
renum = renumbered
ed = editorial change
rep = repealed
exp = expires/expired or ceases/ceased to have
rs = repealed and substituted
effect
s = section(s)/subsection(s)
gaz = gazette
/rule(s)/subrule(s)/order(s)/suborder(s)
LA = Legislation Act 2003
sch = Schedule(s)
LIA = Legislative Instruments Act 2003
SLI = Select Legislative Instrument
(md) = misdescribed amendment can be given
SR = Statutory Rules
effect
sub ch = Sub‑Chapter(s)
(md not incorp) = misdescribed amendment
sub div = Subdivision(s)
cannot be given effect
sub pt = Subpart(s)
mod = modified/modification
underlining = whole or part not
No. = Number(s)
commenced or to be commenced
Ord = Ordinance
Name
Registration
Commencement
Application, saving and transitional provisions
2013 No. R43
29 Nov 2013 (F2013L02009)
30 Nov 2013
2015 No. R1/MRCC1
30 Mar 2015 (F2015L00376)
1 Apr 2015
s 3, 4
2015 No. R45
24 Dec 2015 (F2015L02130)
sch pt A: 25 Dec 2015 (s 2(1) item 2) sch pt B: 1 Jan 2016 (s 2(1) item 3)
sch 1 (items 2, 3): 9 am (A.C.T.) 10 Dec 2025 (s 2)
—
Provision affected
How affected
s 1B....................
rep LIA s 48D
Part 1
s 2.....................
am F2023L01754
s 3.....................
am 2015 No. R1/MRCC1; F2015L02130; am F2017L01618; am F2018L00847; am F2019L01387; ed C8; am F2020L00437; am F2020L01026; am F2024L01444; am F2025L01331
s 4.....................
rs. 2015 No. R1/MRCC1
Part 2
s 7.....................
rs. F2017L01618
s 11....................
rs. F2017L01618
s 11AA..................
ad 2015 No. R1/MRCC1; am F2019L01387
s 11A...................
ad 2015 No. R1/MRCC1; am. F2017L01618; am F2019L01387
Heading preceding s 11B......
rep 2015 No. R1/MRCC1
s 11B...................
rs 2015 No. R1/MRCC1; am F2019L01387; ed C8; am F2020L01026; am F2025L01331
s 11C...................
rep. 2015 No. R1/MRCC1; ad F2019L01387
s 11D...................
ad F2019L01387
Heading preceding s 12.......
rep F2015L02130
Part 3
s 16....................
am 2015 No. R1/MRCC1; am. F2017L01618; am F2020L00437; am F2025L01331
s 16AAA………………………..
ad F2020L00437
s 16AA..................
ad. 2015 No. R1/MRCC1; am F2017L01618
s 16A...................
am F2017L01618; am F2020L00100; am F2023L01754; am F2025L00191; am F2025L00659; am F2025L01647
s 16AB..................
ad. 2015 No. R1/MRCC1
s 21A...................
ad F2015L02130; am F2020L01026; am F2024L01444
Part 4
s 24A...................
rep. 2015 No. R1/MRCC1
s 24....................
am 2015 No. R1/MRCC1
s 24B...................
rep. 2015 No. R1/MRCC1
s 25....................
rs. 2015 No. R1/MRCC1
Part 5
s 26....................
rs F2015L02130
s 27....................
rep F2015L02130
s 28....................
rep F2015L02130
s 29....................
rep F2015L02130
s 30....................
am F2015L02130
s 32A...................
ad F2024L01444
Part 5A
s 37....................
rs. 2015 No. R1/MRCC1
Part 5B<br>s 40A...................
<br>am F2021L00138
Part 6
s 41....................
rs. F2017L01618
s 42....................
rep. F2017L01618
s 43....................
rs 2015 No. R1/MRCC1; am F2017L01618; am F2019L01387
s 45....................
ad. 2015 No. R1/MRCC1; am. F2017L01618
s 45A...................
ad. 2015 No. R1/MRCC1; am F2017L01618
s 45B...................
ad F2019L01387; am F2020L01026
s 47....................
am. 2015 No. R1/MRCC1
Schedule 1
Schedule 1................
rs F2015L02130; rs F2016L01872; rs F2017L00705; rs F2017L01618; rs F2018L00847; am F2020L01026; am F2024L01444
Schedule 2
Schedule 2………………………
ad F2020L00100; am F2020L01026; am F2023L01754; rs F2025L00191; rs F2025L01647